Clinical trial
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute…
NCT00401739 · CSL Limited, Industry · Completed
Key facts
| NCT number | NCT00401739 |
|---|---|
| Title | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia |
| Official title | Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia |
| Lead sponsor | CSL Limited, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia (AML) |
| Intervention type | Drug |
| Interventions | CSL360 |
| Enrollment | 40 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Nov 20, 2006 |
| Last update posted | Sep 16, 2009 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: